WRF
BMRN icon

Waddell & Reed Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Waddell & Reed Financial’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-762,764
Closed -$65.3M – 458
2019
Q2 		$65.3M Sell
762,764
-1,761,209
-70% -$151M 0.16% 173
2019
Q1 		$224M Sell
2,523,973
-336,902
-12% -$31.2M 0.56% 41
2018
Q4 		$244M Sell
2,860,875
-376,063
-12% -$35.8M 0.69% 33
2018
Q3 		$314M Sell
3,236,938
-100,408
-3% -$10M 0.7% 30
2018
Q2 		$314M Buy
3,337,346
+160,247
+5% +$14M 0.73% 27
2018
Q1 		$258M Buy
3,177,099
+729,223
+30% +$62.6M 0.58% 40
2017
Q4 		$218M Buy
2,447,876
+66,102
+3% +$5.75M 0.48% 52
2017
Q3 		$222M Buy
2,381,774
+1,241,693
+109% +$110M 0.49% 55
2017
Q2 		$104M Buy
1,140,081
+8,678
+0.8% +$789K 0.23% 119
2017
Q1 		$99.3M Sell
1,131,403
-23,021
-2% -$2.05M 0.21% 130
2016
Q4 		$95.6M Sell
1,154,424
-23,522
-2% -$2.02M 0.21% 132
2016
Q3 		$109M Buy
1,177,946
+70,441
+6% +$6.63M 0.23% 120
2016
Q2 		$86.2M Buy
1,107,505
+71,710
+7% +$6.1M 0.18% 145
2016
Q1 		$85.4M Sell
1,035,795
-56,596
-5% -$4.6M 0.16% 159
2015
Q4 		$114M Buy
1,092,391
+1,198
+0.1% +$125K 0.19% 137
2015
Q3 		$115M Sell
1,091,193
-372,454
-25% -$49.8M 0.19% 133
2015
Q2 		$200M Buy
1,463,647
+22,481
+2% +$2.79M 0.29% 98
2015
Q1 		$180M Sell
1,441,166
-78,772
-5% -$8.35M 0.25% 100
2014
Q4 		$137M Sell
1,519,938
-110,000
-7% -$9.15M 0.19% 129
2014
Q3 		$118M Buy
1,629,938
+33,976
+2% +$2.23M 0.16% 146
2014
Q2 		$99.3M Buy
1,595,962
+590,149
+59% +$35.7M 0.15% 162
2014
Q1 		$68.6M Buy
1,005,813
+905,813
+906% +$66.8M 0.1% 195
2013
Q4 		$7.03M Buy
+100,000
New +$6.79M 0.01% 472

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Waddell & Reed Financial's BMRN Position: Q3 2019 in Review

Waddell & Reed Financial sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 762,764 shares — an estimated $65.3M sold.

Waddell & Reed Financial first reported a position in BMRN in Q4 2013 and held it in 23 quarters. The position peaked at $314M in Q2 2018. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

  • Waddell & Reed Financial reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Waddell & Reed Financial sold 762,764 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $65.3M.
  • Waddell & Reed Financial first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 23 quarters.
  • Waddell & Reed Financial's BioMarin Pharmaceuticals position peaked at $314M in Q2 2018.
  • 436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Waddell & Reed Financial's 13F filing for Q3 2019, filed 14 Nov 2019.